Corneal Neovascularization: A Combined Approach of Bevacizumab and Suramin Showed Increased Antiangiogenic Effect Through Downregulation of BFGF and P₂X₂

References

• Chang JH. Corneal neovascularization. Current Opinion in Ophthalmology. 2001;12:242–49.
   PubMed Web of Science ®Google Scholar
• Schmid MK, Bachmann LM, Fas KAG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2015;99(2):141–46.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab and ranibizumab. JAMA Ophthalmol. 2017 Jun 1;135(6):558–68.
   PubMed Web of Science ®Google Scholar
• Erdurmus M, Totan Y. Subconjuntival bevacizumab for corneal neovascularization. Graefe’s Arch Clin Exp Ophthalmol. 2007;245:1577–79.
   PubMed Web of Science ®Google Scholar
• Menzel-Severing J. Emerging techniques to treat corneal neovascularisation. Eye. 2012;26:2–12.
   PubMed Web of Science ®Google Scholar
• Guler M, Yilmaz T, Ozercan I, Elkiran T. The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol. 2009;147(4):703–08.
   PubMed Web of Science ®Google Scholar
• Kaya MK, Demir T, Bulu H, Akpolat N, Turqut B. Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization. Clin Exp Ophthalmol. 2015;43(5):449–57.
   PubMed Web of Science ®Google Scholar
• Lee HS, Chung SK. The effect of subconjunctival suramin on corneal neovascularization in rabbits. Cornea. 2010;29(1):86–92.
   PubMed Web of Science ®Google Scholar
• Lopez ES, Rizzo MM, Croxatto JO, Mazzolini G, Gallo JE. Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization. Cancer Chemother Pharmacol. 2011;67(3):723–28.
   PubMed Web of Science ®Google Scholar
• Tártara LI, Palma SD, Allemandi D, Ahumada MI, Llabot JM. New mucoadhesive polymeric film for ophthalmic administration of acetazolamide. Recent Pat Drug Deliv Formul. 2014;8(3):224–32.
   PubMedGoogle Scholar
• Quinteros D, Vicario-de-la-Torre M, Andrés-Guerrero V, Palma S, Allemandi D, Herrero-Vanrell R. Hybrid formulations of liposomes and bioadhesive polymers improve the hypotensive effect of the melatonin analogue 5-MCA-NAT in rabbit eyes. PLoS One. 2014 Oct 20;9(10):e110344.
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–47.
   PubMed Web of Science ®Google Scholar
• Moshfeghi A, Rosenfeld P, Puliafito C, Michels S, Marcus E, Lenchus J, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Ophthalmology. 2006;113:2002–11.
   PubMed Web of Science ®Google Scholar
• Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein- basic fibroblast growth factor is stored within basement membrane. Am J Pathol. 1988;130(2):393–400.
   PubMed Web of Science ®Google Scholar
• Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22:201–07.
   PubMed Web of Science ®Google Scholar
• Chris O, Cui J, Matsubara J. FarzinForooghian. Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells. Br J Ophthalmol. 2013;97(8):1074–78.
   PubMed Web of Science ®Google Scholar
• Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR. Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci. 2009;50:1659–65.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, Saya H, Suda T. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. Jem. 2009;206(5):1089–102.
   PubMed Web of Science ®Google Scholar
• Lee HS, Hos D, Blanco T, Bock F, Reyes NJ, Mathew R, Cursiefen C, Dana R, Saban DR. Involvement of corneal lymphangiogenesis in a mouse model of allergic eye disease. Invest Ophthalmol Vis Sci.. 2015;56(5):3140–48.
   PubMed Web of Science ®Google Scholar
• Bocci G. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol. 1999;43:205–12.
   PubMed Web of Science ®Google Scholar
• Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther. 1994;64:445–75.
   PubMed Web of Science ®Google Scholar
• Kathir KM, Kumar TK, Yu C. Understanding the mechanism of the antimitogenic activity of suramin. Biochemistry. 2006 Jan 24;45(3):899–906.
   PubMed Web of Science ®Google Scholar
• Villalona-Calero MA, Wientjes MG, Otterson GA, Kanter S, Young D, Murgo AJ, Fisher B, DeHoff C, Chen D, Yeh TK, et al. Phase I study of low dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2003 Aug 15;9(9):3303–11.
   PubMed Web of Science ®Google Scholar
• Waltenberger J, Mayr U, Frank H, Hombach V. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol. 1996;28(7):1523–29.
   PubMed Web of Science ®Google Scholar
• Ray F, Huang W, Slater M, Barden J. Purinergic receptor distribution in endothelial cells in blood vessels: a basis for selection of coronary artery grafts. Atherolsclerosis. 2002;162:55–61.
   PubMed Web of Science ®Google Scholar
• Sarman S, Mancini J, Van Der Ploeg I, Croxatto JO, Kvanta A, Gallo JE. Involvement of purinergic P2 receptors in experimental retinal neovascularization. Curr Eye Res. 2008;33(3):285–91.
   PubMed Web of Science ®Google Scholar
• Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez–Barrios P. Inhibition of experimental corneal neovascularisation by Bevacizumab (Avastin). Br J Ophthalmol. 2007;91(6):804–07.
   PubMed Web of Science ®Google Scholar
• Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Short- and long-term safety profile and efficacy of topical bevacizumab (avastin) eye drops against corneal neovascularization. Graefe’s Arch Clin Exp Ophthalmol. 2009;247(10):1375–82.
   PubMed Web of Science ®Google Scholar
• Bock F, Onderka J, Dietrich T, Bachmann B, Kruse F, Paschke M, Zahn G, Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545–52.
   PubMed Web of Science ®Google Scholar
• DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol. 1997;151(3):671–77.
   PubMed Web of Science ®Google Scholar
• Loukovaara S, Gucciardo E, Repo P, Vihinen H, Lohi J, Jokitalo E, Salven P, Lehti K2. Indications of lymphatic endothelial differentiation and endothelial progenitor cell activation in the pathology of proliferative diabetic retinopathy. ActaOphthalmol. 2015;93(6):512–23.
   PubMed Web of Science ®Google Scholar
• Chen D, Song SH, Wientjes MG, Yeh TK, Zhao L, Villalona-Calero M, Otterson GA, Jensen R, Grever M, Murgo AJ, Nontoxic suramin as a chemosensitizer in patients: dosing noogram development. Pharma Res. 2006;23(6):1265–74.
   Google Scholar
• Villalona-Calero M, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, et al. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol. 2008;19(11):1903–09.
   PubMed Web of Science ®Google Scholar
• Quinteros DA, Lopez ES, Couto JL, Maletto BA, Allemandi DA, Palma SD, Gallo JE. Evaluation of the performance of an ophthalmic thermosensitive hydrogel containing combination of suramin and bevacizumab. Curr Pharm Des. 2016;22(43):6587–94.
   PubMed Web of Science ®Google Scholar